Skip to content

Replimune Group REPL Interest Expense

Interest Expense at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$12.9M+48.3%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$3.51M+30.5%
Erasca, Inc. logo
Erasca, Inc.ERAS
$4.45M-6.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M+200%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$13.87M+2.5%
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseDebt.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's interest expense?
Replimune Group (REPL) reported interest expense of $1.47M in Q4 2025.
How has Replimune Group's interest expense changed year-over-year?
Replimune Group's interest expense increased by 1.1% year-over-year, from $1.45M to $1.47M.
What is the long-term trend for Replimune Group's interest expense?
Over 3 years (2022 to 2025), Replimune Group's interest expense has grown at a 73.0% compound annual growth rate (CAGR), from $1.12M to $5.78M.
What does interest expense mean?
Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.